Nothing Special   »   [go: up one dir, main page]

Ferraz et al., 2009 - Google Patents

Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients

Ferraz et al., 2009

View PDF
Document ID
4943337429393205494
Author
Ferraz R
Marques N
Froeder L
Menon V
Siliano P
Baxmann A
Heilberg I
Publication year
Publication venue
Urological Research

External Links

Snippet

It had been suggested that lactic acid bacteria (LAB) may degrade oxalate in the intestinal lumen, reducing urinary oxalate excretion. We aimed to evaluate the effect of a LAB mixture containing Lactobacillus casei (LC) and Bifidobacterium breve (BB)(LC+ BB) upon urinary …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER, CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using micro-organisms or enzymes

Similar Documents

Publication Publication Date Title
Ferraz et al. Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients
Sircana et al. Gut microbiota, hypertension and chronic kidney disease: recent advances
Guida et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial
Lieske et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation
Sanz et al. Understanding the role of gut microbes and probiotics in obesity: how far are we?
Xiao et al. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers
Grases et al. Absorption and excretion of orally administered inositol hexaphosphate (IP6 or phytate) in humans
Firouzi et al. The effects of prebiotic, probiotic, and synbiotic supplementation on blood parameters of renal function: A systematic review and meta-analysis of clinical trials
UA71621C2 (en) Use of combined bacterial composition as dietary or pharmaceutical supplement for preventing or treating hyperoxaluria
Trautvetter et al. High phosphorus intake and gut-related parameters–results of a randomized placebo-controlled human intervention study
Al-Wahsh et al. Acute probiotic ingestion reduces gastrointestinal oxalate absorption in healthy subjects
Patel et al. Therapeutic prospective of a spore-forming probiotic—Bacillus clausii UBBC07 against acetaminophen-induced uremia in rats
AU2014210581A1 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
Chen et al. Gut microbiota affect the formation of calcium oxalate renal calculi caused by high daily tea consumption
Millán Rodríguez et al. The relationship between calcium oxalate lithiasis and chronic proinflammatory intestinal dysbiosis pattern: a prospective study
Cabré et al. Nutritional and metabolic issues in inflammatory bowel disease
US10231989B2 (en) Renal insufficiency progression inhibitor, prophylactic agent for renal insufficiency and indoxyl sulfate production inhibitor
Kesavelu et al. Common gastrointestinal distress among infants: role of optimal nutritional interventions
JP2009229456A (en) Irritable bowel syndrome determining marker
US20190307802A1 (en) Probiotic compositions including immune modulators
Soliman et al. The oxalate-lowering effect of functional stirred yogurt in a rat model
US20190091270A1 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
Mazur-Kurach et al. Effects of probiotic supplementation on selected health indices among a group of competitive cyclists (effect of probiotic therapy on health indices)
US11382928B2 (en) Nutritional composition with resistant starch useful in the treatment of neoplastic diseases
Felix How gut microbiome correlates with oxalate, butyrate and kidney stones formation